Astellas Initiates Phase 3 Clinical Trial of Evrenzo (Rosadustat) for Pediatric Chronic Kidney Disease Anemia
Evrenzo's Strategy to Expand Pediatric Indications
Global pharmaceutical company Astellas Pharma has commenced a global Phase 3 clinical trial (NCT05970172) of its oral anemia treatment, Evrenzo (rosadustat), to expand its indications to include pediatric and adolescent patients with chronic kidney disease (CKD). Evrenzo is approved by the European Medicines Agency (EMA) for the treatment of anemia in adult CKD patients, but its approval was rejected by the U.S. FDA due to concerns about cardiovascular safety. This pediatric trial represents Astellas' strategic move to overcome the stagnation in the adult market and secure a new growth engine in a market with significant unmet medical needs. By securing the pediatric indication, Astellas can expect to enhance its corporate value through price advantages and exclusivity benefits.
Overcoming the Limitations of Existing Injectable Standard Treatments
Currently, pediatric patients with CKD anemia are treated with injectable erythropoiesis-stimulating agents (ESAs) such as darbepoetin alfa. However, frequent intravenous and subcutaneous injections in young patients cause significant physical and psychological distress, and pose a considerable burden on caregivers. Evrenzo, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), is an oral tablet that promotes natural red blood cell production in the body, significantly improving ease of administration. By shifting the treatment paradigm from injectable to oral medications, Evrenzo has the potential to significantly improve treatment compliance in pediatric patients.
Precise Design and Challenges of the Global Phase 3 Trial
This Phase 3 trial (NCT05970172) is a multinational study conducted on pediatric and adolescent patients aged 2 to 17 years, with a three-times-weekly (TIW) oral administration and a maximum observation period of 52 weeks. The key to the clinical design is to precisely adjust the dosage based on the patient's weight and hemoglobin levels, and to ensure a safety profile. Given that the FDA Advisory Committee (AdComm) previously recommended against approval in the adult trial due to concerns about cardiovascular adverse events, demonstrating safety will be the most critical factor in this pediatric trial. Astellas plans to overcome this challenge by implementing a customized dosage adjustment protocol that takes into account the metabolic characteristics of pediatric patients.
Value and Competitive Landscape of the Pediatric Anemia Market
The global CKD anemia treatment market is expected to grow from approximately $977.4 million in 2025 to approximately $1.4503 billion in 2032, indicating significant growth potential. In the adult market, competitors such as GSK's daprodustat and Akebia's vadadustat are sharing the market. However, the pediatric indication area is a blue ocean with high barriers to entry for competitors due to the difficulty of conducting clinical trials and stringent safety standards. If Astellas can secure the pediatric CKD anemia market with Evrenzo, it is expected to exercise dominant market power and rapidly absorb the existing injectable market.
Astellas Pharma's ongoing Phase 3 clinical trial of Evrenzo for pediatric chronic kidney disease (CKD) anemia (NCT05970172) represents a critical milestone in overcoming regulatory hurdles in the adult market and securing a high-value niche market. The CKD anemia treatment market, projected to grow from $977.4 million in 2025 to $1.4503 billion in 2032, presents an opportunity for Evrenzo to demonstrate the convenience of oral administration in pediatric patients, potentially replacing existing injectable erythropoiesis-stimulating agent (ESA) standard treatments. Given the previous Complete Response Letter (CRL) from the U.S. FDA Advisory Committee (AdComm), which raised safety concerns (thrombosis, etc.) with a 13-to-1 vote, securing safety data in the Phase 3 trial will be a key determinant for future market access in the United States. With GSK's daprodustat and Akebia's vadadustat competing in the adult market, Astellas' potential to be the first to secure a pediatric indication could lead to long-term market exclusivity and pricing advantages.
Source: ClinicalTrials.gov (api_ct)